In the Nathanson dataset, melanoma patients with high TIIClnc signature scores had prolonged survival time (Figure 5L), and melanoma patients with high TIIClnc signature scores tended to respond to anti-CTLA-4 immunotherapy (Figure 5M). This evidence concerns the gene CTLA4 and melanoma.